15. 封入体筋炎 Inclusion body myositis Clinical trials / Disease details

臨床試験数 : 42 / 薬物数 : 33 - (DrugBank : 11) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 123

diseases per page:

Showing 1 to 10 of 42 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05721573 (ClinicalTrials.gov)	February 28, 2023	1/2/2023	A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis	A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Effic ...	Inclusion Body Myositis	Drug: ABC008	Abcuro, Inc.	Syneos Health	Recruiting	40 Years	N/A	All	231	Phase 2/Phase 3	United States
2	NCT04789070 (ClinicalTrials.gov)	July 1, 2022	15/2/2021	Phase III Trial of Sirolimus in IBM	A Double-Blind Randomised Controlled Trial (dbRCT) Phase III Trial Investigating the Effect of Sirol ...	Inclusion Body Myositis	Drug: Sirolimus;Drug: Placebo	University of Kansas Medical Center	The Perron Institute	Recruiting	45 Years	N/A	All	140	Phase 3	United States;Australia
3	NCT05032131 (ClinicalTrials.gov)	September 2021	27/8/2021	Cell Therapy for IBM by Muscle Injection of ADSVF: a Phase I Trial	Cell Therapy for Inclusion Body Myositis(IBM) by Muscle Injection of Autologous Uncultured Adipose-D ...	Inclusion Body Myositis	Biological: ADSVF	Assistance Publique - Hôpitaux de Paris	NULL	Not yet recruiting	45 Years	80 Years	All	32	Phase 1	NULL
4	NCT04659031 (ClinicalTrials.gov)	May 25, 2021	25/11/2020	A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Pati ...	A Phase 1, Open-Label, Ascending Dose Study of ABC008 in Adult Patients With Inclusion Body Myositis ...	Inclusion Body Myositis	Drug: ABC008	Abcuro, Inc.	NULL	Recruiting	40 Years	N/A	All	30	Phase 1	Australia
5	NCT04421677 (ClinicalTrials.gov)	August 20, 2020	18/5/2020	Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis	Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis	Inclusion Body Myositis;Sporadic Inclusion Body Myositis	Drug: Phenylbutyrate Oral Tablet	University of Kansas Medical Center	NULL	Completed	18 Years	N/A	All	10	Phase 1	United States
6	EUCTR2019-000749-11-GB (EUCTR)	09/10/2019	20/06/2019	An open-label, non-randomized trial to investigate the efficacy and safety of early versus delayed s ...	An open-label, non-randomized trial to investigate the efficacy and safety of early versus delayed s ...	Sporadic Inclusion Body Myositis(sIBM) MedDRA version: 21.1;Level: LLT;Classification code 10075052; ...	Product Name: Arimoclomol Product Code: BRX-345 INN or Proposed INN: ARIMOCLOMOL Other descriptive name ...	Orphazyme A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;United Kingdom
7	NCT04049097 (ClinicalTrials.gov)	May 20, 2019	1/4/2019	Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial	An Open-label, Non-randomized Trial to Investigate the Efficacy and Safety of Early Versus Delayed S ...	Inclusion Body Myositis	Drug: Arimoclomol	Orphazyme	University of Kansas Medical Center;University College, London	Completed	45 Years	N/A	All	121	Phase 3	United States;United Kingdom
8	NCT03710941 (ClinicalTrials.gov)	February 19, 2019	15/10/2018	Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intraveno ...	Sporadic Inclusion Body Myositis	Drug: REGN2477+REGN1033;Drug: Matching placebo	Regeneron Pharmaceuticals	NULL	Withdrawn	45 Years	75 Years	All	0	Phase 2	NULL
9	EUCTR2017-004903-33-GB (EUCTR)	18/06/2018	05/04/2018	Study of Arimoclomol in patients with Inclusion Body Myositis (IBM)	Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis(IBM)A Randomized, Double-blind, Placebo-Co ...	Sporadic Inclusion Body Myositis(sIBM) MedDRA version: 21.1;Level: LLT;Classification code 10075052; ...	Product Name: Arimoclomol Product Code: BRX-345 INN or Proposed INN: ARIMOCLOMOL Other descriptive name ...	Orphazyme A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 2;Phase 3	United States;United Kingdom
10	NCT03440034 (ClinicalTrials.gov)	May 22, 2018	14/11/2017	Study of Pioglitazone in Sporadic Inclusion Body Myositis	An Open-Label Pilot Study of Pioglitazone in Sporadic Inclusion Body Myositis	Myositis;Inclusion Body Myositis;Muscular Diseases;Musculoskeletal Disease;Neuromuscular Diseases;Ne ...	Drug: Pioglitazone	Johns Hopkins University	NULL	Completed	50 Years	N/A	All	19	Phase 1	United States

First Previous1 2 3 4 5Next Last